Abbott Laboratories lopinavir

The U.S. has consistently opposed compulsory licensing by other countries. In January 2001, the U.S. requested a WTO panel against Brazil to prevent Brazilian "local manufacture" of AIDS drugs (WTO 2001). Under international pressure, the U.S. withdrew the panel request in the months leading up to the Fourth WTO Ministerial Conference in Doha (Thomas 2001 t Hoen 2002). More recently, U.S. groups attacked Brazil in July 2005 over a proposed compulsory license of Kaletra (lopinavir and ritonavir), an AIDS fixed-dose combination drug. The patent owner, Abbott Laboratories, reached a voluntary price reduction agreement with Brazil which made the formal compulsory license unnecessary, another demonstration of the power of compulsory licenses to improve access (Benson 2005). 

USAN Lopinavir Trade name Kaletra Abbott Laboratories Launched 2000... 

Kaletta (Lopinavir/ritonavir). Abbott Laboratories. US Prescribing information, January 2007. 

Kaletra Tablets (Lopinavir/Ritonavir). Abbott Laboratories Ltd. UK Summary of product characteristics, March 2007. 

Kaletra (ritonavir/lopinavir) Antiviral (HIV) Abbott Laboratories... 

Rosenberg J, Reinhold U, Liepold B, Berndl G, Alan L, Ghosh S, Brietenbach J (2005) A solid pharmaceutical dosage formulation comprising lopinavir, European Patent, Abbott Laboratories. EP 2283844 Al... 

Similar labeling language also in the labeling of INVIRASE (Roche Laboratories) (saquinavir mesylate) capsules, December 2003 KALETRA (Abbott) (lopinavir/ritonavir) capsules, (lopinavir/ritonavir) oral solution, February 2004 and LEXIVA (GlaxoSmithKline) (fosamprenavir calcium) tablets. May 2004. 

---

See also in sourсe #XX -- [ ]

---